FDA Grants Priority Review to Epcoritamab-bysp for Relapsed or Refractory Follicular Lymphoma

If approved, epcoritamab (DuoBody CD3xCD20; AbbVie, Genmab) would be the first and only subcutaneous bispecific antibody for treatment in this patient population.

Related Keywords

United States ,American ,Epcoritamab Epkinly Tepkinly ,Epcoritamab Duobody ,Mariana Cota Stirner ,European Medicines Agency ,Exposition Of The American Society Hematology ,Drug Administration ,Cota Stirner ,Annual Meeting ,American Society ,Drug Administration Grants Priority Review ,Difficult To Treat Relapsed ,Refractory Follicular Lymphoma ,Bispecific Antibody Epcoritamab ,Shows Strong ,Durable Treatment Response ,Follicular Lymphoma ,Refractory Follicular ,